JPRN-UMIN000026858招募中2 期
Randomized phase II/III study of gemcitabine and nab-paclitaxel therapy versus S-1 and concurrent radiotherapy as neoadjuvant treatment for Borderline resectable pancreatic cancer - GABARNANCE Trial
EPOC A1601/JASPAC070 个研究点目标入组 110 人开始时间: 2017年4月6日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 79years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. History of gemcitabine, nab-paclitaxel and fluorouracil 2. poor control of diarrhea 3. Use of Coumadin, Phenytoin and Flucytosine 4. Allergic to gemcitabine and nab-paclitaxel 5. Computed tomography contrast media allergy 6. Intestinal pneumonia 7. Moderate amount of ascites or pleural effusion 8. Active infection 9. Poor control of diabetes mellitus 10. Ongoing active other malignancy 11. Active peptic ulcer 12. Serious comorbid conditions 13. Myocardial infarction within last 6 months 14. Systemic steroid therapy 15. Serious psychiatric diseases 16. Planning a baby or pregnancy 17. Planning a baby 18. Judged unable to guarantee safety
研究者
相似试验
进行中（未招募）
2 期
GABARNANCE TrialJPRN-jRCTs031180319Ikeda Masafumi110
进行中（未招募）
不适用
Randomised phase II/III study comparing gemcitabine followed by gemcitabine plus concomitant radiation (50.4 Gy) versus gemcitabine alone after curative pancreaticoduodenectomy for pancreatic head cancerEUCTR2005-000933-39-DEEuropean Organisation for Research and Treatment of Cancer538
已完成
2 期
A randomized phase II study of Gemcitabine or Gemcitabine + S-1 as adjuvant chemotherapy for resected biliary tract cancerBiliary tract cancer (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder carcinoma)JPRN-UMIN000007244Adjuvant Therapy for BTC Research Group130
已完成
2 期
Randomized phase II study comparing Gemcitabine versus TS-1 for advanced bile duct cancerAdvanced bile duct cancerJPRN-UMIN000001595Osaka International Cancer Institute Department of Hepatobiliary and pancreatic Oncology110
进行中（未招募）
1 期
Full-dose single-agent chemotherapy (gemcitabine) or reduced-dose combination chemotherapy as first palliative treatment for fragile patients with advanced pancreatic cancer.Pancreatic CancerEUCTR2021-005067-52-DKAalborg University Hospital, Department of Oncology100